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The type I transmembrane protein with epidermal growth
factor and two follistatin motifs 2 (TMEFF2) is expressed in
brain and prostate and overexpressed in prostate cancer, but its
role in this disease is unclear. Several studies have suggested that
TMEFF2 plays a role in suppressing the growth and invasive
potential of human cancer cells, whereas others suggest that the
shed portion of TMEFF2, which lacks the cytoplasmic region,
has a growth-promoting activity. Here we show that TMEFF2
has a dual mode of action. Ectopic expression of wild-type full-
length TMEFF2 inhibits soft agar colony formation, cellular
invasion, andmigration and increases cellular sensitivity to apo-
ptosis. However, expression of the ectodomain portion of
TMEFF2 increases cell proliferation. Using affinity chromatog-
raphy and mass spectrometry, we identify sarcosine dehydro-
genase (SARDH), the enzyme that converts sarcosine to glycine,
as aTMEFF2-interacting protein. Co-immunoprecipitation and
immunofluorescence analysis confirms the interaction of
SARDH with full-length TMEFF2. The ectodomain does not
bind to SARDH. Moreover, expression of the full-length
TMEFF2 but not the ectodomain results in a decreased level of
sarcosine in the cells. These results suggest that the tumor sup-
pressor activity of TMEFF2 requires the cytoplasmic/trans-
membrane portion of the protein and correlates with its ability
to bind to SARDH and to modulate the level of sarcosine.
The transmembrane protein with an epidermal growth fac-
tor and two follistatin motifs 2 (TMEFF2)3 is an evolutionarily
conserved type I transmembrane protein expressed in the
embryo (1, 2) and selectively in the adult brain and prostate
(3–5). The extracellular (ecto-) domain can be cleaved from the
membrane in an ADAM17/-secretase-dependent fashion (6,
7) and consists of an epidermal growth factor-like motif and
two follistatin motifs. The cytoplasmic domain contains a
potential G-protein activation motif (2). A critical role for this
protein in tumorigenesis is suggested by the fact that it is up-
regulated in a significant fraction of primary and metastatic
prostate tumors (3–5, 8). In fact, ectopic expression or the addi-
tion of purified recombinant TMEFF2 ectodomain promotes
neuronal cell survival (9), cell growth (6), and phosphorylation
of erbB4 and ERK1/2 (2, 6). However, it has also been suggested
that TMEFF2 functions as a tumor suppressor because ectopic
expression of full-length TMEFF2 demonstrates in vitro anti-
proliferative effects (4, 10) and suppresses tumor growth in vivo
in nude mouse xenografts (10). Consistent with a tumor sup-
pressor activity, Tmeff2 has been shown to be hypermethylated
in a number of cancer types (Refs. 11–16 and references
therein), and the Tmeff2 promoter is repressed by c-Myc (17).
Recently, sarcosine, a glycine derivative, was identified as a
potential marker of prostate cancer progression (18). Sarcosine
levels were highest in metastatic cancer, and in urine, its levels
were higher in men with prostate cancer than in controls.
Importantly, using cell lines, Sreekumar et al. (18) provided
evidence that the enzymes involved in sarcosinemetabolismact
as regulators of cell invasion and therefore as potential thera-
peutic targets for prostate cancer. The addition of sarcosine or
knockdown of sarcosine dehydrogenase (SARDH), the enzyme
that converts sarcosine into glycine, in benign prostate epithe-
lial cells enhances invasion. Conversely, lowering the levels of
glycine N-methyltransferase, the enzyme that catalyzes the
conversion of glycine into sarcosine, in DU145 cells reduces
their invasiveness.
Here we present data to demonstrate that TMEFF2 interacts
with SARDH and regulates the cellular levels of sarcosine. The
data also indicate that there is an association between the ability
of TMEFF2 to bind SARDH andmodulate the level of sarcosine
and its ability to act as a tumor suppressor. Further, this activity
requires the transmembrane and/or cytoplasmic portion of the
protein. Ectopic expression of TMEFF2 results in monolayer
and anchorage-independent growth inhibition and decreased
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sarcosine-induced cellular motility. However, the TMEFF2
ectodomain fails to bind to SARDH and to modulate the cellu-
lar levels of sarcosine and reverts the tumor suppressor pheno-
type, demonstrating no effect on anchorage-independent
growth and an increase in monolayer growth.
EXPERIMENTAL PROCEDURES
Proliferation Assay—Cells were seeded at 3,000–5,000 cells/
well in 96-well plates. After incubation for the indicated times,
MTT reagent (Sigma) was added at a concentration of 5 mg/ml
in phenol red-free RPMI containing 1% FBS. Following a 3.5-h
incubation at 37 °C, 200 l of dimethyl sulfoxide (DMSO)
(Sigma) was added to each well, and optical density was mea-
sured at 562 nm.
Apoptosis Assay—To induce apoptosis, 30,000 cells/well
were plated into 6-well plates and treated with 2 or 3 M stau-
rosporine (Sigma) for 24 h.Cellswere thenwashedwith 1PBS
and stained with 1 l of annexin V-FITC reagent (BioVision)
and 1 l of a 5 g/ml propidium iodide solution (Invitrogen) to
stain necrotic cells. Cells were analyzed by flow cytometry
(FACScan, BD Biosciences).
Anchorage-independent Growth—2,500–3,500 cells were
suspended in 0.35% agarose in DMEMcontaining 5% FBS. This
suspension was overlaid onto a solidified layer of 0.4% agarose
in a 60-mm plate. Fresh DMEM was maintained on top plates
during a 14–21-day incubation, at which time the cells were
stained with 0.005% crystal violet, photographed, and counted.
Migration Assays—Cell migration was assayed using cell cul-
ture Boyden chambers (BD Biosciences) and NIH 3T3 condi-
tioned medium as chemoattractant. Following a 24-h incuba-
tion, cells adhering to the bottom of the membrane were fixed
with 70% ethanol, stained with 0.1% crystal violet, and photo-
graphed. The inserts were then treated with 10% acetic acid,
and absorbance was measured at 562 nm. Migration was also
assessed by a wound-healing assay essentially as described (19).
To analyze sarcosine-induced migration, the cells were grown
in the presence of 50 M sarcosine or alanine for a total of 96 h,
and TMEFF2 expression was induced by the addition of doxy-
cycline (250 ng/ml) for 48 h, before the wound was made.
Affinity Chromatography and Mass Spectrometry Analysis—
TMEFF2-Myc-His was overexpressed in FreeStyle 293-F cells
(Invitrogen) and captured on nickel-Sepharose 6 Fast Flow
beads (GE Healthcare) using 20 mM imidazole-containing
buffer. Beads were washed in 20 mM imidazole buffer, and
TMEFF2-Myc-His complexes were eluted with 500–800 mM
imidazole-containing buffer. Eluted proteins were resolved by
SDS-PAGE on 4–12% NuPAGE Novex Bis-Tris gel (Invitro-
gen) and stained with Imperial protein stain (Pierce). Bands of
interest were excised and digested with trypsin (Sigma) and
subjected to MALDI-mass spectrometry proteomic analysis
using a Voyager DE Pro-MALDI-TOFmass spectrometer. Pro-
tein database searching was performed with Mascot peptide
mass fingerprint (Matrix Science) against the human Swiss-
Prot protein database.
Co-immunoprecipitation—HEK293T cells were transfected
with the indicated constructs and lysed in cell lysis buffer (Cell
Signaling). The lysate (50 g) was incubated with antibody-
coupled Dynabeads (Invitrogen) for 30 min at 4 °C. Beads were
washed with PBS, and the immunoprecipitated proteins,
remaining on the beads, were eluted in 50 mM glycine, pH 2.8,
or by heating at 70 °C for 10 min in 50 mM glycine, pH 2.8, plus
NuPAGE LDS sample buffer (Invitrogen), resolved by SDS-
PAGE, and analyzed byWestern blot using the appropriate pri-
mary horseradish peroxidase (HRP)-conjugated antibody. For
co-immunoprecipitation analysis using LNCaP or 22Rv1
lysates, 100–250g of total proteinwas used, and elution of the
target proteinwas in SDS sample buffer. To increase sensitivity,
subsequent Western blot analysis was performed using the
appropriate primary antibody and a light chain-specific sec-
ondary antibody (Jackson ImmunoResearch Laboratories).
Immunostaining and Live Imaging—Cells were seeded on
poly-L-lysine- and laminin (Sigma)-coated coverslips, trans-
fected with TMEFF2 and SARDH-Myc-His expression con-
structs, and incubated for 24–48 h. Cells were fixed with cold
4% paraformaldehyde in PBS (USB/Affymetrix), permeabilized
with 0.1% Triton X-100 in PBS, and blocked with 5% normal
goat serum in 0.1% PBS  0.1% Tween-20. Samples were incu-
bated with the indicated primary antibodies overnight at 4 °C
and then with the corresponding goat anti-mouse FITC (Santa
Cruz Biotechnology) or goat anti-rabbit Alexa Fluor 568 (Invit-
rogen) secondary antibody at room temperature and mounted
with medium containing DAPI (Santa Cruz Biotechnology).
Images were obtained with a Zeiss LSM 510 confocal micro-
scope. For live cell protein imaging,HEK293T cells were seeded
in collagen-coated glass bottomculture dishes (MatTek), trans-
fected with SARDH-YFP and TMEFF2-CFP, and incubated for
24–48 h.
Sarcosine Assay—Cells were washed with PBS, lysed in sar-
cosine assay buffer (MBL International), and briefly sonicated.
Insoluble material was removed by centrifugation at 4 °C. The
cellular levels of sarcosine were measured in the supernatant
using a sarcosine assay kit (MBL International), and the data
were normalized to the level of total L-amino acid present in the
same supernatant (L-amino acid quantification kit, MBL
International).
Statistical Analyses—Data are expressed asmean S.D. Dif-
ferences were analyzed by paired, two-tailed Student’s t test. A
p value 0.05 was considered statistically significant.
RESULTS
Increased Expression of TMEFF2 Inhibits Cell Growth in
HEK293T Cells—To investigate the function of TMEFF2 in
tumorigenesis, we determined whether ectopic expression of
this protein could affect cellular proliferation. HEK293T cells
stably expressing untagged (TMEFF2-wt) or c-Myc-His-tagged
(TMEFF2-Myc-His) TMEFF2 proteins, alongwith control cells
transfected with empty vector or untransfected cells, were gen-
erated for this purpose (Table S1 and supplemental Fig. S1A).
Overexpression of either untagged (Fig. 1A) or C-terminal
c-Myc-His-tagged TMEFF2 (Fig. 1B) in HEK293T cells
decreased cell numbers by 20–30%with respect to the untrans-
fected cells or the cells transfected with the empty vector. The
presence of the C-terminal c-Myc-His tag did not change the
effect of TMEFF2 on cell growth. Therefore, subsequent exper-
iments were done using the c-Myc-His-tagged form of the
protein.
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To further characterize the nature of the alteration in prolif-
eration rate, FACS analysis was used to investigate the effect of
TMEFF2 in apoptosis and cell cycle progression. HEK293T
cells stably transfected with TMEFF2-Myc-His or with the
empty vector as a control were induced to undergo apoptosis
with staurosporine, a protein kinase inhibitor that triggers both
caspase-dependent and caspase-independent apoptotic path-
ways (20, 21). The presence of TMEFF2 in HEK293T cells had
no effect on the number of apoptotic cells. However, it
increased the sensitivity of the cells to staurosporine-in-
duced apoptosis when compared with empty vector trans-
fected cells (Fig. 1, C and D). TMEFF2 had a small effect on
cell cycle, resulting in a slightly increased cell number in G1
(supplemental Fig. S1B). Supporting this observation, our
preliminary array data indicate that overexpressing TMEFF2
results in increased expression of the cyclin-dependent
kinase inhibitor p15 and decreased expression of cyclin E2
(supplemental Fig. S1C).
FIGURE 1. TMEFF2 inhibits proliferation and anchorage-independent growth and sensitizes cells to apoptosis. A–F, stable expression of untagged (A) or
c-Myc-His (B–F)-tagged form of TMEFF2 decreases proliferation of HEK293T cells (A and B), sensitizes the cell to an apoptotic stimulus (C and D), and inhibits
anchorage-independent growth (E and F). Overexpression of TMEFF2 was confirmed by Western blot analysis (A and B, insets). The effect of TMEFF2 on growth
(A and B) was determined using an MTT assay after 96 h of growth. The A562 at 96 h was normalized first to the value obtained at zero time (to correct for plating
variability) and then to the value obtained for the parental cell line (HEK293T; A) or the cell line carrying the empty vector (EV) (B) as control. The effect of TMEFF2
on apoptosis of HEK293T cells (C and D) was determined in the presence of staurosporine or the vehicle, as a control, by analyzing the number of annexin
V-positive cells and comparing it with the numbers obtained when expressing the empty vector. C and D, a representative image of the flow cytometry analysis
(C) and percentage of apoptotic cells (D). E and F, a representative image showing anchorage-independent growth (E) and number of colonies formed by
HEK293T cells stably expressing TMEFF2-Myc-His or the empty vector as a control (F) after 14 days of growth. Data shown are mean  S.D. of at least three
independent experiments with multiple replicates. Several clones were tested to rule out that the effects are due to the insertion site. *, p  0.05, and **, p 
0.01.
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To further investigate the tumor suppressor potential of
TMEFF2, we assessed its ability to promote anchorage-inde-
pendent growth using a soft agar growth assay. HEK293T cells
stably expressing TMEFF2-Myc-His formed5-fold fewer col-
onies, which were of smaller size than cells carrying the empty
vector (Fig. 1, E and F). Thus, TMEFF2 suppresses the forma-
tion and the growth of HEK293T colonies in soft agar. Overex-
pression of TMEFF2 had no effect on themigration or invasion
ability of HEK293T cells as measured using Boyden chambers
(not shown).
TMEFF2 Inhibits Sarcosine-induced Cell Migration of Pros-
tate Epithelial Cells—Because the expression of TMEFF2 is
mainly restricted to brain and prostate (3–5), we sought to ana-
lyze the effect of TMEFF2 overexpression in prostate cells. We
selected RWPE1 cells, derived from non-neoplastic human
prostatic epithelial cells (22), which express very low levels of
endogenousTMEFF2 as demonstrated by quantitative RT-PCR
(not shown). Full-length TMEFF2 was introduced into the
RWPE1 cells by retroviral gene transfer to generate an RWPE1
cell line that inducibly expresses TMEFF2 with the addition of
doxycycline to the growth medium (RWPE1-TMEFF2i). Con-
trol cells were transduced with the transactivator construct
only (RWPE1-tet). High level of expression of TMEFF2 in the
RWPE1-TMEFF2i cell line upon the addition of doxycycline
was demonstrated (Fig. 2A). To test whether TMEFF2 affects
the growth rate of RWPE1 cells, RWPE1-TMEFF2i cells were
grown in the absence (no TMEFF2 expression) and presence
(TMEFF2 expression) of doxycycline, and the effect of TMEFF2
on the growth rate was determined. No significant effect of
TMEFF2 on the growth rate of RWPE1 cells was observedwhen
compared with the RWPE1-tet cells (Fig. 2B).
The addition of sarcosine to RWPE cells increases themigra-
tion and invasion ability of these cells (18).We therefore tested
whether TMEFF2 can reverse the sarcosine-inducedmigration
effect. Briefly, RWPE1-TMEFF2i cells were grown in the pres-
ence of sarcosine or alanine and doxycycline to induceTMEFF2
expression before their migration potential was analyzed using
a wound-healing assay. The effect of TMEFF2 was investigated
by comparing themigration of RWPE1-TMEFF2i cells with the
migration ability of the control cell line, RWPE1-tet, both in the
presence of doxycycline. The addition of sarcosine resulted in
an increase in migration of the RWPE1-tet cells (Fig. 2C) when
compared with cells grown in the presence of alanine. Overex-
pressing TMEFF2 in these cells blocked the increased migra-
FIGURE 2. TMEFF2 inhibits migration of RWPE cells. A, Western blot demonstrating the induction of TMEFF2 expression in response to doxycycline (Dox, 250
ng/ml) in the RWPE1-TMEFF2i cell line. -Actin was used as loading control. B, the effect of TMEFF2 overexpression on the growth of RWPE1 cells was
determined using an MTT assay after 96 h of growth. The A560 at 96 h was normalized first to the value obtained at zero time (to correct for plating variability)
and then to the value obtained for same cells grown in the absence of doxycycline. C, the effect of TMEFF2 on migration was determined using a 24-h
wound-healing assay. The cells were grown in the presence of 50 M alanine (ALA) or sarcosine (SAR) and 250 ng/ml doxycycline to induce the expression of
TMEFF2. The RWPE1-tet cell line was used as a control. A representative image (top) and quantification of the results (bottom) are shown. D, migration of cells
from a random experimental repeat was also analyzed using Boyden chambers. Cells adhering to the bottom of the membrane were fixed, stained with crystal
violet, and photographed. Single cell clones were analyzed and gave similar results. Data shown are mean  S.D. of three independent experiments with
multiple replicates. *, p  0.05, and **, p  0.01.
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tion associated with the addition of sarcosine (Fig. 2C). The
addition of alanine also had a small effect onmigration that was
also reversed by TMEFF2 overexpression. Migration data
obtained using Boyden chambers confirmed the results of the
wound assay (Fig. 2D). These results suggest that TMEFF2 can
block the intrinsic and the sarcosine-induced migration poten-
tial of RWPE1 cells. In addition, using a Boyden chamber inva-
sion assay, we observed that TMEFF2 overexpression was also
able to reverse the intrinsic and the sarcosine-induced invasion
ability of the cells (supplemental Fig. S2). It is worth noting that
although in HEK293T cells TMEFF2 negatively affects mono-
layer and anchorage-independent growth but has no effect on
migration or invasion, the reverse seems to be true when
TMEFF2 is overexpressed in RWPE cells, indicative of the cell
line-specific effect of TMEFF2.
TMEFF2 Binds Specifically to Sarcosine Dehydrogenase—To
gain insight into themolecularmechanisms of TMEFF2 action,
we sought to search for candidate functional partner(s) of
TMEFF2 by screening TMEFF2 affinity complexes using mass
spectrometry. Freestyle 293-F cells were transfected with
TMEFF2-Myc-His, and TMEFF2 complexes were purified
using a histidine affinity column, resolved in a polyacrylamide
gel, and subjected toMALDI-TOF/MS analysis. Binding to and
elution of the TMEFF2 protein from the column were verified
by Western blot (supplemental Fig. S3). To identify specific
TMEFF2 interactors, we compared TMEFF2 and empty vector
affinity eluates and chose those bands that were mainly repre-
sented only in the TMEFF2 affinity eluates. Furthermore, to
qualify as a specific interactor, a protein had to be identified in
at least two out of four independent TMEFF2 affinity/MS anal-
ysis. With six peptides displaying a probability-based Mowse
score of 53 (23), one of the candidate proteins identified was
SARDH.Additional searches provided up to nine different pep-
tides corresponding to SARDH (Table 1).
An interaction between TMEFF2 and SARDH was con-
firmed by co-immunoprecipitation (co-IP) analysis (Fig. 3). A
plasmid expressing SARDH from a CMV promoter (pCMV-
SARDH) was transiently transfected into HEK293T cells stably
expressing the TMEFF2-Myc-His protein or the empty vector,
and anti-TMEFF2 immunocomplexes were analyzed for the
presence of SARDH by Western blotting. SARDH was clearly
detected by the SARDH antibody in the TMEFF2 immunopre-
cipitates from cells expressing the TMEFF2-Myc-His construct
(Fig. 3A, lanes 1 and 3), but not the empty vector (Fig. 3A, lanes
2 and 4), demonstrating that the presence of TMEFF2 is
required to detect SARDH. Two different antibodies, c-Myc
and aTMEFF2-specific antibody,were used to immunoprecipi-
tate the TMEFF2-Myc-His protein with the same results (Fig.
3A, compare lanes 1 and 2 with lanes 3 and 4). However, when
the TMEFF2-specific antibody and strong elution conditions
were used, we observed an additional higher molecular weight
band specific for SARDH also present in the whole cell lysates
(supplemental Fig. S3). The same band was also observed when
the co-IP experiments were conducted with endogenous pro-
teins (see below). As negative controls, two isotype-matched,
anti-4EBP1 (Fig. 3A, lane 6) and anti-eIF2 (not shown) antibod-
TABLE 1
Sarcosine dehydrogenase peptides identified by mass spectrometry
analysis of TMEFF2 affinity complexes

































FIGURE 3. TMEFF2 interacts with sarcosine dehydrogenase. A, TMEFF2
associates with SARDH in cells. Cell lysates from HEK293T cells overexpressing
SARDH and TMEFF2-Myc-His or the empty vector (EV) as a control were immu-
noprecipitated with the indicated antibodies (IP) anti-c-Myc, anti-TMEFF2,
anti-SARDH, or anti-4EBP1 (control) and immunoblotted (IB) with anti-
SARDH or anti-TMEFF2 HRP-conjugated antibodies. The size of the band cor-
responding to SARDH (black arrowhead) lies between the 55–70-kDa marker.
The size of the band corresponding to TMEFF2 (empty arrowhead) lies
between the 40 –55-kDa marker. WCL, whole cell lysate; FT, flow-through.
B, the TMEFF2 ectodomain (ECTO) fails to associate with SARDH in cells. A cell
lysate from HEK293T cells overexpressing SARDH and ECTO-Myc-His was
immunoprecipitated with anti-Myc or anti-4EBP1 (control) and immuno-
blotted with anti-SARDH-HRP antibody. SARDH is indicated with a black
arrowhead. C, association of endogenous TMEFF2 and SARDH proteins. Cell
lysates from LNCaP or 22Rv1 cells were immunoprecipitated with anti-
TMEFF2 antibody or IgG as a control and immunoblotted with anti-SARDH
antibody. The wedge shape indicates increasing amount of lysate used (150 –
250 g of total protein). The arrows indicate the position of the major SARDH
bands (between the 55–70- and 70 –100-kDa markers). The small arrowhead
indicates a band with a migration similar to the IgG heavy chain (star).
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ies were utilized for the IP step. SARDH was not co-immuno-
precipitated when either one of these antibodies was used for
the IP step, demonstrating that the interaction between
SARDH and TMEFF2 is specific. Reciprocal co-IP experiments
using anti-SARDH antibodies for immunoprecipitation and
TMEFF2 antibodies forWestern blot were also performed (Fig.
3A, lanes 7–10) and confirmed the TMEFF2-SARDH interac-
tion (Fig. 3A, lane 10).
To further validate the specificity of the TMEFF2-SARDH
interaction, we performed co-IP studies as described above
with cells that ectopically express the TMEFF2 ectodomain
(ECTO-Myc-His; supplemental Fig. S3 for schematic). The
results indicate that SARDH was not present in the co-immu-
noprecipitates obtained from the ECTO-Myc-His-expressing
cells (Fig. 3B, lanes 1–5). The ECTO-Myc-His protein is readily
secreted into the medium (see below), but it is also abundant in
the cellular lysates and able to bind to the nickel or antibody
affinity columns (supplemental Fig. S3), ruling out that the lack
of interaction reflects the absence of intracellular protein or
failure to bind to the columns.
To better establish the physiological relevance of the above
results, the TMEFF2-SARDH interaction was also analyzed in
two prostate cancer cells, LNCaP and 22RV1, known to express
some endogenous TMEFF2. Co-IP studies indicated that
SARDH is present in the TMEFF2 co-immunoprecipitates
obtained using LNCaP or 22Rv1 cell lysates and therefore that
the interaction occurs and is detectable even with the low
endogenous levels of these proteins (Fig. 3C). Polyclonal rabbit
IgG was used as a negative control. The ability of endogenous
TMEFF2 to bind to the antibody affinity column was verified
(supplemental Fig. S3). Collectively, these results indicate that
TMEFF2 specifically interacts with SARDH and that the pres-
ence of the transmembrane and/or cytoplasmic domains is
essential for this interaction.
TMEFF2 Co-localizes with Sarcosine Dehydrogenase—The
possibility that TMEFF2 and SARDH can temporarily localize
to the same cellular compartment was examined by immuno-
fluorescence co-localization studies. HEK293T cells ectopically
expressing TMEFF2 were transiently transfected with a tagged
SARDH-Myc-His construct and incubated with polyclonal
TMEFF2 antibody (to detect TMEFF2) and monoclonal Myc
antibody (to detect SARDH). The localization of the proteins
was subsequently visualized by confocal microscopy using
Alexa Fluor 568- and FITC-conjugated secondary antibodies.
Cells expressing TMEFF2 exhibited fluorescence concentrated
at the plasmamembrane but also in the cytoplasm in a punctate
pattern (Fig. 4A and supplemental Fig. S4). Confirming pub-
lished observations, SARDHmainly localized to the mitochon-
dria (36), with less fluorescence detected in the cytoplasm (Fig.
4A and supplemental Fig. S4). Co-localization of the proteins in
the cytoplasm was evidenced by overlapping fluorescence sig-
nals (Fig. 4A and supplemental Fig. S4, yellow). As anticipated
based on the results from the co-IP analysis, the ectodomain of
TMEFF2 did not demonstrate co-localization with SARDH
(Fig. 4B).
Co-localization of TMEFF2 and SARDH was also examined
in living cells. For this purpose, TMEFF2 and SARDH were
C-terminally tagged with cyan (CFP) and yellow fluorescent
proteins (YFP) to generate TMEFF2-CFP and SARDH-YFP,
respectively. The resulting fusion proteins were expressed in
HEK293T cells, and the localization of the fluorescent proteins
was imaged by confocal microscopy (Fig. 4C and supplemental
Fig. S4). Interestingly, when TMEFF2-CFP and SARDH-YFP
were co-expressed, they co-localize in an area surrounding the
nuclear envelope that could correspond to the Golgi apparatus.
Co-localization of endogenously expressed proteins was
examined using LNCaP and 22Rv1 cells as described above and
in Cytospin preparations of cell suspensions. As observed with
the TMEFF2-overexpressing cells, co-localization of the pro-
teins in the cytoplasm was evidenced by overlapping fluores-
cence signals (supplemental Fig. S4, yellow).
Overexpression of the Full-length TMEFF2 Results in De-
creased Cellular Sarcosine Levels—SARDH catalyzes sarcosine
to glycine conversion and, consequently, siRNA to SARDH
results in increased sarcosine levels. Interestingly, this also
results in an increase in the invasion potential of the cells, link-
ing sarcosine metabolism with tumorigenesis (18). Because
TMEFF2 interacts with SARDH, we hypothesized that
TMEFF2modulates SARDHactivity to promote changes in cell
growth and/or invasion.We analyzed changes in sarcosine lev-
els in response to TMEFF2 overexpression. Lysates were pre-
pared from HEK293T cells stably transfected with the
TMEFF2-Myc-His and ECTO-Myc-His expression constructs
or with the empty vector as a control, and sarcosine levels were
determined in the resulting cell lines. Overexpression of the
ectodomain (ECTO-Myc-His) does not affect sarcosine levels
(Fig. 5). However, overexpression of TMEFF2 resulted in a sig-
nificant decrease in the amount of sarcosine with respect to the
lysates expressing the empty vector control (Fig. 5), whereas
having no effect on SARDH expression as measured by West-
ern blot (supplemental Fig. S5). Expression of TMEFF2 also
resulted in a small but significant decrease in the amount of
sarcosine in RWPE1 cells (supplemental Fig. S5) that could
account for the observed effect of TMEFF2 on the migration
and invasion properties of this cell line. Although it is possible
that the observed decrease in sarcosine levels is due to an indi-
rect effect of TMEFF2, the physical interaction between
SARDH and TMEFF2 demonstrated above suggests that the
reduction in sarcosine may be due to an increase in SARDH
activity mediated by its interaction with TMEFF2. A small but
detectable effect of TMEFF2 on the activity of commercially
available purified Pseudomonas sp. SARDH enzyme further
supports this possibility (supplemental Fig. S5).
The Ectodomain Region of TMEFF2 Acts as a Ligand to Pro-
mote Increased Cell Growth—Based on our findings, we also
hypothesized that because of the inability of the TMEFF2
ectodomain to interact with SARDH and to affect the levels of
cellular sarcosine, it would not demonstrate a tumor suppres-
sor phenotype.We therefore expressed the ectodomain formof
TMEFF2 (ECTO-Myc-His) in HEK293T cells and analyzed its
effect on cell growth. As reported previously (6), overexpres-
sion of the ectodomain resulted in increasedmonolayer growth
when compared with empty vector transfected cells (Fig. 6A).
In contrast to full-length TMEFF2, overexpression of the
ectodomain did not have any effect on anchorage-independent
growth in soft agar or cellular invasion (data not shown).
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The ectodomain region expressed throughout these experi-
ments corresponds essentially to the naturally shed ectodomain
of the TMEFF2 protein. Because it lacks a transmembrane
domain, it is directly secreted and can be detected in the con-
ditionedmedium (supplemental Fig. S6). It was therefore likely
that the observed effect on monolayer growth was due to the
secreted form of the ectodomain acting as a ligand from the
outside of the cell. To examine this possibility, we determined
the effect that conditionedmedium collected from cell cultures
overexpressing full-length TMEFF2 had on the growth of two
different cell lines, HEK293T and RWPE1 (Fig. 6, B–D). Expo-
nentially growing HEK293T cells transfected with the
TMEFF2-Myc-His construct were starved for 24 h, and the
conditioned medium was collected and supplemented with
0.4% FBS. The presence of TMEFF2 sequences in the condi-
tioned medium was analyzed byWestern blot using antibodies
against the TMEFF2 ectodomain or against the c-Myc tag (Fig.
6C). The collected conditionedmediumwas used to replace the
growthmedium of cultures of HEK293T and RWPE1 cells, and
the growth rate of these cells was measured at different time
FIGURE 4. TMEFF2 co-localizes with sarcosine dehydrogenase. A, HEK293T cells ectopically expressing TMEFF2 and SARDH-Myc-His were fixed and stained
with anti-TMEFF2 and anti-c-Myc (to detect SARDH) antibodies. Thin and thick filled arrows point to the membranous and vesicular localization of TMEFF2,
respectively. B, HEK293T cells ectopically expressing the TMEFF2 ectodomain (ECTO) and SARDH-Myc-His were treated and processed for immunofluorescent
staining as in A. C, in vivo co-localization of TMEFF2 and SARDH. HEK293T cells were transfected with TMEFF2-CFP and SARDH-YFP fusion constructs, and living
cells were observed 24 h later. CFP fluorescence is shown as green signal, YFP fluorescence is shown as red signal, and co-localization of CFP and YFP is illustrated
by yellow signal. The confocal images in each panel are representative of more than 40 fields observed over four or five different experiments. Scale bars
represent 10 m.
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intervals after the medium replacement. As a control, condi-
tioned medium collected from vector transfected HEK293T
cultures was used. The addition of conditioned medium from
the TMEFF2-Myc-His-overexpressing cultures resulted in a
significant growth increase of HEK293T and RWPE1 cells (Fig.
6D). Similar results were observed when conditioned medium
fromECTO-Myc-His-overexpressing cells was used to feed the
HEK293T or RWPE1 cell cultures (supplemental Fig. S6).
These results suggest that the ectodomainmay act as a ligand to
promote increased growth rate of HEK293T and RWPE1 cells.
DISCUSSION
Deregulated expression of TMEFF2 has been documented in
a variety of tumor types (3, 8, 11–16, 25, and references therein).
However, the relationship of TMEFF2 to the biology of tumor
development or suppression and the molecular bases of these
activities remain unknown. The present study reveals a novel
functional and physical interaction between TMEFF2 and
SARDH, an enzyme involved in sarcosine metabolism, and
characterizes the role of this interaction in the tumorigenic
activity of TMEFF2.We demonstrate that TMEFF2 expression
results in a decrease in the level of cellular sarcosine and that
this effect correlateswith its ability to act as a tumor suppressor.
SARDH is responsible for conversion of sarcosine to glycine
and is therefore one of the regulators of sarcosine levels in the
cell. Because sarcosine is formed as a result of glycine methyla-
tion, the decrease in sarcosine levels that we observed with
TMEFF2 overexpression could be due to an effect on the global
cellular amino acid metabolism and/or methylation activity or
to an effect on the activity of the SARDH enzyme. Our data
indicating that TMEFF2 physically interacts with SARDH favor
the latter possibility. This interpretation bestows an active role
for sarcosine in tumorigenesis consistent with data indicating
that in cell culture, the addition of sarcosine promotes cell inva-
sion of prostate epithelial cells (18). Our results demonstrate
that the ability of TMEFF2 to decrease the cellular sarcosine
FIGURE 5. TMEFF2 affects the levels of cellular sarcosine. Overexpression
of TMEFF2 significantly reduces the levels of sarcosine in HEK293T cells. Circles
on the box plot indicate outliers. Data shown are the result of six different
experiments with multiple replicates.
FIGURE 6. The TMEFF2 ectodomain promotes cell growth. A, the effect of the TMEFF2 ectodomain on growth was determined in HEK293T cells stably
transfected with the ECTO-Myc-His construct using an MTT assay. After 96 h of growth, the A562 was measured and normalized first to the value obtained at zero
time and then to the value obtained for the cell line carrying the empty vector (EV) as control. B, schematics of the experiment used to determine the effect of
the secreted ectodomain on cell growth (shown in D). C, detection of ectodomain sequences in the conditioned medium using the specified antibodies.
Because the ectodomain region is produced by TMEFF2 shedding from the membrane, it is not detected by the c-Myc antibody to the C-terminal region.
Specificity was further confirmed by the addition of TNF to induce shedding. (See supplemental Fig. S6.) D, effect of the secreted ectodomain on the growth
of HEK293T and RWPE1 cells was determined by MTT assay after 48 h of growth on conditioned medium obtained from cells expressing TMEFF2-Myc-His
(TMEFF2 CM) or the empty vector as control (EV-CM). The A562 at 48 h was normalized first to the value obtained at zero time and then to the value obtained for the
same cell line grown in the empty vector conditioned medium. Data shown are mean  S.D. of three independent experiments with multiple replicates. *, p  0.05.
TMEFF2 Binds SARDH and Modulates Sarcosine Levels
16098 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286 • NUMBER 18 • MAY 6, 2011
levels correlates with its function. Expression of full-length
TMEFF2 decreases cellular sarcosine levels and leads to a
tumor suppressor phenotype, whereas expression of the ecto-
domain does not alter sarcosine levels and leads to reversion of
the tumorigenic phenotype. These results also suggest that the
effect of TMEFF2 on sarcosine levels requires the presence of a
transmembrane domain and/or the cytoplasmic tail and could
possibly be mediated by the G-protein-activating domain pres-
ent in this region.
As shown under “Results,” the ectodomain promotes cellular
proliferation, confirming previous reports (6, 9). Cleavage of
the extracellular domain of TMEFF2 is induced by proinflam-
matory cytokines and regulated by ADAM17 (6, 7) and, as pro-
posed (6), this effect could contribute to explain the opposing
results described for TMEFF2, such as growth suppression
dependent on full-length TMEFF2, its ability to modulate sar-
cosine levels, and proliferation dependent on regulated release
of the ectodomain, which is unable to modulate sarcosine lev-
els. Interestingly, a soluble isoform of TMEFF2 has also been
described (25), and although its role is unknown, we predict
that it will not modulate sarcosine levels. The identification of
proteins with both pro-oncogenic and anti-oncogenic activities
has been previously described, emphasizing the complexity of
cellular events that occur during tumorigenesis (26–30). Sev-
eral mechanisms account for the switch in oncogenic activity
including the cellular context, the type of tumor, the activation
of different pathways, or the presence of different isoformswith
opposing roles (26–30).
Similar to TMEFF2, TMEFF1, the only other knownmember
of the TMEFF family, demonstrates different activities depend-
ing on the presence of the cytoplasmic tail and its anchorage to
the membrane. In Xenopus, TMEFF1 inhibits TGF signaling
by blocking the nodal co-receptor Cripto (31). The follistatin
and EGFmotifs contribute to this effect; however, anchorage to
the membrane is also essential for this function. Conversely,
TMEFF1 blocking of BMP2-mediated signaling requires the
cytoplasmic domain of the protein, whereas deletion of either
the follistatin or the EGF motifs does not interfere with this
function (32). A function for the TMEFF1 ectodomain has not
been described. TMEFF1 and TMEFF2 grossly differ in their
tissue distribution. TMEFF1 is more widely distributed than
TMEFF2, and even in brain, where both proteins are ex-
pressed, they exhibit distinct distribution patterns (33). Never-
theless, their high level of sequence similarity suggests that
TMEFF1 and TMEFF2 could be playing similar roles in differ-
ent tissues and/or developmental stages.
Using confocal microscopy, we have observed TMEFF2
localization to the membrane but also to the cytoplasm, where
it appears in a punctate pattern. This vesicle-like immunoreac-
tivity has also been described in neurons (34, 35), and it has
been proposed to correspond to vesicles translocating newly
synthesized TMEFF2 to the cell surface and/or cleaved
TMEFF2 to the nucleus. SARDHhas been described essentially
as a mitochondrial enzyme (36); however, our results suggest
that it can also be found in the cytosol and/or the Golgi appa-
ratus, where it could be interacting with TMEFF2 during traf-
ficking.We predict that this interactionmodifies the activity of
SARDH and, ultimately, the mitochondrial and/or cytosolic
levels of sarcosine. Several mitochondrial enzymes have been
described as tumor suppressors, for example, succinate dehy-
drogenase and fumarase hydratase (37) or a mitochondrial
form of the sirtuin deacetylases, SIRT3 (38). Similar to these
enzymes, SARDH should be considered a tumor suppressor
because its inactivation leads to sarcosine accumulation and
increased invasion. Interestingly, the level of SARDH protein
has been reported to decrease in hepatocellular carcinoma (39).
By binding to SARDH, TMEFF2 could bemodulating the activ-
ity of SARDH and therefore the cellular level of sarcosine, sug-
gesting that it may function as a “secondary” tumor suppressor.
Whether the tumor suppressor activity of TMEFF2 depends
entirely on SARDH or on additional interacting protein/signal-
ing pathways is currently under investigation.
The results presented here indicate that the role of TMEFF2
in tumorigenesis correlates, at least partially, with its ability to
bind to SARDH and modulate the cellular levels of sarcosine.
However, how does sarcosine promote tumor invasion? Sarco-
sine is an endogenous amino acid with several important bio-
logical functions: (i) it participates in one-carbon metabolism
essential for protein and nucleotide synthesis and DNA meth-
ylation (40), and (ii) it is a competitive inhibitor of the type I
glycine transporter (GlyT1), a glycine transporter found in
brain (41). It is therefore possible that the addition of exoge-
nous sarcosine and its subsequent metabolism affect the meth-
ylation and/or synthetic ability of the cell; alternatively, sarco-
sine may have a yet unidentified role, for example, similar to its
role on GlyT1, as an agonist/antagonist of a factor involved in
tumorigenesis. This last possibility is supported by the fact that
blocking sarcosine metabolism also promotes cellular invasion
due to sarcosine accumulation.
Increasing evidence links sarcosine metabolism with disease
state, including cancer (prostate, liver) and brain disease.
Although the phenotypic expression of altered sarcosine
metabolism is pleiotropic in several cell types, these cell type-
and isoform-specific differences suggest that a broad range of
biologic responses is mediated by TMEFF2 and sarcosine.
Because TMEFF2 is also differentially expressed in brain, it is
reasonable to hypothesize that its role theremay also be related
to sarcosine metabolism. In fact, TMEFF2 was identified in a
genome-wide association study as a factor involved in schizo-
phrenia (42). Whether the role of TMEFF2 in schizophrenia is
related to its ability tomodulate the level of sarcosine and there-
fore the activity of GlyT1 is not yet certain, but sarcosine is
currently being investigated as a treatment for schizophrenia
(24). The complex biology of TMEFF2 offers insight into met-
abolic regulation of cancer and perhaps other disease states.
The contribution of different TMEFF2 isoforms to this biology
and the regulation of their expression remain to be defined.
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